Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Summary
Artiva Biotherapeutics announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York. The company develops cell therapies for autoimmune diseases and highlighted its lead program, AlloNK, which is being tested in multiple clinical trials. Artiva also said it plans to start a Phase 3 registrational trial for AlloNK in refractory rheumatoid arthritis in 2026. The notice is primarily an investor relations update and does not announce a transaction, new hire, or product release.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected